Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform
Date
2018Journal
Communications BiologyPublisher
Nature ResearchType
Article
Metadata
Show full item recordAbstract
Emerging and re-emerging zoonotic viral diseases are major threats to global health, economic stability, and national security. Vaccines are key for reducing coronaviral disease burden; however, the utility of live-attenuated vaccines is limited by risks of reversion or repair. Because of their history of emergence events due to their prevalence in zoonotic pools, designing live-attenuated coronavirus vaccines that can be rapidly and broadly implemented is essential for outbreak preparedness. Here, we show that coronaviruses with completely rewired transcription regulatory networks (TRNs) are effective vaccines against SARS-CoV. The TRN-rewired viruses are attenuated and protect against lethal SARS-CoV challenge. While a 3-nt rewired TRN reverts via second-site mutation upon serial passage, a 7-nt rewired TRN is more stable, suggesting that a more extensively rewired TRN might be essential for avoiding growth selection. In summary, rewiring the TRN is a feasible strategy for limiting reversion in an effective live-attenuated coronavirus vaccine candidate that is potentially portable across the Nidovirales order. Copyright 2018, The Author(s).Sponsors
This research was supported by NIH NIAID grants U19-AI107810, R01-AI108197 and U54-AI057157 to R.S.B. and 5F32AI080148 to R.L.G.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061268931&doi=10.1038%2fs42003-018-0175-7&partnerID=40&md5=303935554b051b9e586291b236e3a061; http://hdl.handle.net/10713/12392ae974a485f413a2113503eed53cd6c53
10.1038/s42003-018-0175-7
Scopus Count
Collections
Related articles
- A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.
- Authors: Agnihothram S, Yount BL Jr, Donaldson EF, Huynh J, Menachery VD, Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS
- Issue date: 2014 Mar 25
- Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.
- Authors: Regla-Nava JA, Nieto-Torres JL, Jimenez-Guardeño JM, Fernandez-Delgado R, Fett C, Castaño-Rodríguez C, Perlman S, Enjuanes L, DeDiego ML
- Issue date: 2015 Apr
- The relationship of severe acute respiratory syndrome coronavirus with avian and other coronaviruses.
- Authors: Jackwood MW
- Issue date: 2006 Sep
- Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
- Authors: Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N
- Issue date: 2015 Mar
- Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
- Authors: Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS
- Issue date: 2011 Jan